Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
121. |
ECCT/24/04/02 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr Fredrick Kipyego Sawe Site(s) in Kenya 1. Walter Reed Army Institute of Research -Kericho Site (Kericho county) |
03-07-2024 |
View |
122. |
ECCT/24/06/01 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Raymond Scott McClelland Site(s) in Kenya 1. Pwani Research Centre (Mombasa county) |
02-07-2024 |
View |
123. |
ECCT/24/04/06 | REACH 2 Realizing Effectiveness Across Continents with Hydroxyurea (REACH): A Phase I/II Prospective Trial of Hydroxyurea for Children and Young Adults with Sickle Cell Anaemia |
Principal Investigator(s) 1. Thomas Williams 2. Russell Ware Site(s) in Kenya Kilifi County Referal Hospital |
28-06-2024 |
View |
124. |
ECCT/24/03/04 | MK8591A-053 Trial A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants |
Principal Investigator(s) 1. Elizabeth Anne Bukusi 2. Nelly Rwamba Mugo Site(s) in Kenya 1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county) 2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county) 3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county) |
19-06-2024 |
View |
125. |
ECCT/24/01/03 | Doxy Short Course A Phase 4 Study of a 3-Day Vs. 7-Day Regimen of Doxycycline for the Treatment of Chlamydial Infection. |
Principal Investigator(s) 1. Jackson Nyangaresi Nyandoro 2. Nelly Rwamba Mugo Site(s) in Kenya 1. Pwani Research Centre (Mombasa county) 2. KEMRI CCR-PHRD (Nairobi City county) |
18-06-2024 |
View |
126. |
ECCT/24/02/10 | IMBrave A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA |
Principal Investigator(s) 1. Dr. Pauline Njoki Njiraini Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
09-06-2024 |
View |
127. |
ECCT/24/04/01 | B/F/TAF to DTG/3TC Switch Stud Efficacy, Safety and Tolerability of Switching to DTG/3TC Single Tablet Regimen from B/F/TAF in Older Persons Living with HIV in Kenya |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 2. Kenyatta National Hospital (Nairobi City county) |
02-06-2024 |
View |
128. |
ECCT/24/02/08 | H06_02TP A Phase 2 single-blind, randomized, controlled, single center study to assess the immunogenicity and safety of a 2-dose schedule with GVGH altSonflex1-2-3 vaccine in African infants (H06_02TP) |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI WRP CRC KERICHO |
31-05-2024 |
View |
129. |
ECCT/24/03/03 | DoxyDOT Study Weekly doxycycline DOT for STI prevention among cisgender women taking HIV PrEP in Kisumu, Kenya |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya KEMRI CMR RCTP |
31-05-2024 |
View |
130. |
ECCT/24/01/02 | AP Implementation Research Implementation of WHO recommendations for drugs and approaches to prevent and treat postpartum hemorrhage: a multi-country feasibility, acceptability and cost-effectiveness study |
Principal Investigator(s) 1. Daisy Ruto Jerop Ruto Site(s) in Kenya 36 public health facilities in Makueni County |
30-05-2024 |
View |